No discussions found
Start your discussion
Share your thoughts or question with experts in your field
Start a discussion
Found 1 matching solution for this experiment
Upstream tips |
Protocol tips |
Downstream tips |
|
Monolayer cells were transfected with PKCδ siRNA expression plasmid pKD‐PKCδ‐v3 or pKD‐NegCon‐v3 (Upstate Biotechnology), ON‐TARGET smart pool siRNA, and ON‐TARGET plus siCONTROL Nontargeting Pool (Dharmacon, Lafayette, CO, USA) using Lipofectamine 2000 (Invitrogen). For p38 and ERK1/2 inhibition, cells were transfected with ON‐TARGET smart pool MAPK1 (ERK2) and p38 siRNA duplexes or nonspecific control siRNA duplexes (Dharmacon). Immunoblot analyses showed that expression of PKCδ, ERK1/2, and p38 remained low but detectable, whereas expression of β‐actin was unaffected by siRNA treatment. |
|
Protocol tips |
Monolayer cells were transfected with PKCδ siRNA expression plasmid pKD‐PKCδ‐v3 or pKD‐NegCon‐v3 (Upstate Biotechnology), ON‐TARGET smart pool siRNA, and ON‐TARGET plus siCONTROL Nontargeting Pool (Dharmacon, Lafayette, CO, USA) using Lipofectamine 2000 (Invitrogen). For p38 and ERK1/2 inhibition, cells were transfected with ON‐TARGET smart pool MAPK1 (ERK2) and p38 siRNA duplexes or nonspecific control siRNA duplexes (Dharmacon). Immunoblot analyses showed that expression of PKCδ, ERK1/2, and p38 remained low but detectable, whereas expression of β‐actin was unaffected by siRNA treatment. |
Can't find the product you've used to perform this experiment? It would be great if you can help us by
Adding a product!